EMİNE RABİA KOÇ, ATİLLA İLHAN, ZÜBEYDE AYTÜRK, BURCU ACAR, MUKADDES GÜRLER, AYNUR ALTUNTAŞ, MUSTAFA KARAPİRLİ, ABDURRAHMAN SAİD BODUR

A comparison of hair and serum trace elements in patients with Alzheimer disease and healthy participants

Background/aim: To determine whether there was a difference between serum and hair trace elements' concentrations in patients with Alzheimer disease (AD) and healthy participants. Materials and methods: Hair and serum copper, selenium, zinc, magnesium, manganese, and iron levels were measured by inductively coupled plasma-mass spectrometry in patients with AD and healthy participants, and the obtained results were statistically compared. Results: The mean hair selenium and zinc levels of patients with AD were significantly lower than the levels found for control participants (P < 0.05). Patients with AD had significantly higher mean hair copper and manganese levels than the controls. There were no significant differences between AD patients and controls with respect to the hair iron and magnesium levels (P > 0.05). Hair and serum trace element (copper, selenium, zinc, magnesium, manganese, and iron) levels in patients with AD showed no significant difference according to mini mental test scores or sex (P > 0.05). Conclusion: Some trace element levels may change in patients with AD. Due to the more permanent status, the analysis of these element levels in hair might be superior to blood analysis.

Anahtar Kelimeler:

Alzheimer disease, trace element, hair, serum

A comparison of hair and serum trace elements in patients with Alzheimer disease and healthy participants

Keywords:

Alzheimer disease, trace element, hair, serum,

PDF

___

Grasso G, Giuffrida ML, Rizzarelli E. Metallostasis and amyloid beta-degrading enzymes. Metallomics 2012; 4: 937–949.
Klevay LM. Alzheimer’s disease as copper deficiency. Med Hypotheses 2008; 70: 802–807.
Brewer GJ. Copper toxicity in Alzheimer’s disease: cognitive loss from ingestion of inorganic copper. J Trace Elem Med Biol 2012; 26: 89–92.
Mutter J, Naumann J, Schneider R, Walach H. Mercury and Alzheimer’s disease. Fortschr Neurol Psychiatr 2007; 75: 528– 538.
Hung LW, Barnham KJ. Modulating metals as a therapeutic strategy for Alzheimer’s disease. Future Med Chem 2012; 4:
Bush AI. The metal theory of Alzheimer’s disease. J Alzheimers Dis 2013; 33: 277–281.
Craddock TJ, Tuszynski JA, Chopra D, Casey N, Goldstein LE, Hameroff SR, Tanzi RE. The zinc dyshomeostasis hypothesis of Alzheimer’s disease. PLoS One 2012; 7: e33552.
Faller P. Copper in Alzheimer disease: too much, too little, or misplaced? Free Radic Biol Med 2012; 52: 747–748.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939–944.
Trull TJ, Verges A, Wood PK, Jahng S, Sher KJ. The structure of Diagnostic and Statistical Manual of Mental Disorders (4th edition, text revision) personality disorder symptoms in a large national sample. Personal Disord 2012; 3: 355–369.
Güngen C, Ertan T, Eker E, Yaşar R, Engin F. Reliability and validity of the standardized Mini Mental State Examination in the diagnosis of mild dementia in Turkish population. Turk Psikiyatri Derg 2002; 13: 273–281 (in Turkish with English abstract).
Puchyr RF, Bass DA, Gajewski R, Calvin M, Marquardt W, Urek K, Druyan ME, Quig D. Preparation of hair for measurement of elements by inductively coupled plasma-mass spectrometry (ICP-MS). Biol Trace Elem Res 1998; 62: 167–182.
Akyol O, Ersan F, Akcay F, Altuntas I, Senol M, Sasmaz S. Hair, nail, serum, and urine copper levels in users of copper intrauterine devices and interactions between copper and some other trace elements. Trace Elem Electroly 1997; 14: 124–12 9.
Hammer DI, Finklea JF, Hendricks RH, Shy CM, Horton RJ. Hair trace metal levels and environmental exposure. Am J Epidemiol 1971; 93: 84–92.
Bolognin S, Messori L, Zatta P. Metal ion physiopathology in neurodegenerative disorders. Neuromolecular Med 2009; 11: 223–238.
Johnson WM, Wilson-Delfosse AL, Mieyal JJ. Dysregulation of glutathione homeostasis in neurodegenerative diseases. Nutrients 2012; 4: 1399–1440.
Greenough MA, Camakaris J, Bush AI. Metal dyshomeostasis and oxidative stress in Alzheimer’s disease. Neurochem Int 2013; 62: 540–555.
Sayre LM, Perry G, Smith MA. Oxidative stress and neurotoxicity. Chem Res Toxicol 2008; 21: 172–188.
Weeks BS, Hanna MS, Cooperstein D. Dietary selenium and selenoprotein function. Med Sci Monit 2012; 18: RA127–132.
Akman H, Somuncu S, Dikmen G, Ayva Ş, Soyer T, Doğan P, Çakmak M. Protective effect of selenium on intussusception- induced ischemia/reperfusion intestinal oxidative injury in rats. Turk J Med Sci 2010; 40: 391–397.
Loef M, Schrauzer GN, Walach H. Selenium and Alzheimer’s disease: a systematic review. J Alzheimers Dis 2011; 26: 81–104.
Meseguer I, Molina JA, Jimenez-Jimenez FJ, Aguilar MV, Mateos-Vega CJ, Gonzalez-Munoz MJ, de Bustos F, Orti- Pareja M, Zurdo M, Berbel A et al. Cerebrospinal fluid levels of selenium in patients with Alzheimer’s disease. J Neural Transm 1999; 106: 309–315.
Lyubartseva G, Lovell MA. A potential role for zinc alterations in the pathogenesis of Alzheimer’s disease. Biofactors 2012; 38: 98–106.
Hancock SM, Finkelstein DI, Adlard PA. Glia and zinc in ageing and Alzheimer’s disease: a mechanism for cognitive decline? Front Aging Neurosci 2014; 6: 137.
Haines A, Iliffe S, Morgan P, Dormandy T, Wood B. Serum aluminium and zinc and other variables in patients with and without cognitive impairment in the community. Clin Chim Acta 1991; 198: 261–266.
Panayi AE, Spyrou NM, Iversen BS, White MA, Part P. Determination of cadmium and zinc in Alzheimer’s brain tissue using inductively coupled plasma mass spectrometry. J Neurol Sci 2002; 195: 1–10.
Corrigan FM, Reynolds GP, Ward NI. Hippocampal tin, aluminum and zinc in Alzheimer’s disease. Biometals 1993; 6: 149–154.
Akiyama H, Hosokawa M, Kametani F, Kondo H, Chiba M, Fukushima M, Tabira T. Long-term oral intake of aluminium or zinc does not accelerate Alzheimer pathology in AbetaPP and AbetaPP/tau transgenic mice. Neuropathology 2012; 32:
Becaria A, Lahiri DK, Bondy SC, Chen D, Hamadeh A, Li H, Taylor R, Campbell A. Aluminum and copper in drinking water enhance inflammatory or oxidative events specifically in the brain. J Neuroimmunol 2006; 176: 16–23.
Magaki S, Raghavan R, Mueller C, Oberg KC, Vinters HV, Kirsch WM. Iron, copper, and iron regulatory protein 2 in Alzheimer’s disease and related dementias. Neurosci Lett 2007; 418: 72–76.
Jomova K, Vondrakova D, Lawson M, Valko M. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 2010; 345: 91–104.
Castellani RJ, Moreira PI, Perry G, Zhu X. The role of iron as a mediator of oxidative stress in Alzheimer disease. Biofactors 2012; 38: 133–138.
Rouault TA, Cooperman S. Brain iron metabolism. Semin Pediatr Neurol 2006; 13: 142–148.
Greenough MA, Camakaris J, Bush AI. Metal dyshomeostasis and oxidative stress in Alzheimer’s disease. Neurochem Int 2013; 62: 540–555.
Youdim MB, Yehuda S. The neurochemical basis of cognitive deficits induced by brain iron deficiency: involvement of dopamine-opiate system. Cell Mol Biol (Noisy-le-grand) 2000; 46: 491–500.
González-Domínguez R, García-Barrera T, Gómez-Ariza JL. Homeostasis of metals in the progression of Alzheimer’s disease. Biometals 2014; 27: 539–549.
De Leo ME, Borrello S, Passantino M, Palazzotti B, Mordente A, Daniele A, Filippini V, Galeotti T, Masullo C. Oxidative stress and overexpression of manganese superoxide dismutase in patients with Alzheimer’s disease. Neurosci Lett 1998; 250: 173–176.
Maeda M, Takagi H, Hattori H, Matsuzaki T. Localization of manganese superoxide dismutase in the cerebral cortex and hippocampus of Alzheimer-type senile dementia. Osaka City Med J 1997; 43: 1–5.
Markesbery WR, Ehmann WD, Hossain TI, Alauddin M. Brain manganese concentrations in human aging and Alzheimer’s disease. Neurotoxicology 1984; 5: 49–57.
Gerhardsson L, Lundh T, Minthon L, Londos E. Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 2008; 25: 508–515.